Atika Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Atika Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,000	Closed	-$2.89M	–	97
2018 Q1	$2.89M	Sell	40,000 -16,000	-29%	-$1.17M	0.99%	42
2017 Q4	$3.69M	Buy	56,000 +42,300	+309%	+$2.28M	1.43%	33
2017 Q3	$686K	Buy	+13,700	New	+$661K	0.2%	77
2015 Q3	–	Sell	-8,000	Closed	-$654K	–	70
2015 Q2	$654K	Sell	8,000 -19,500	-71%	-$1.91M	0.29%	65
2015 Q1	$2.55M	Buy	+27,500	New	+$1.77M	1.7%	27

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Atika Capital Management's ESPR Position: Q2 2018 in Review

Atika Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 40,000 shares — an estimated $2.89M sold.

Atika Capital Management first reported a position in ESPR in Q1 2015 and held it in 5 quarters. The position peaked at $3.69M in Q4 2017. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

Atika Capital Management reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
Atika Capital Management sold 40,000 Esperion Therapeutics shares in Q2 2018, an estimated $2.89M.
Atika Capital Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 5 quarters.
Atika Capital Management's Esperion Therapeutics position peaked at $3.69M in Q4 2017.
156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Atika Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.